Indaptus Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Decoy20 / Indaptus Therap
INDP-D101, NCT05651022: Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Recruiting
1/2
120
US
Decoy20, Tislelizumab
Indaptus Therapeutics, Inc, Translational Drug Development
Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
06/27
09/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Decoy20 / Indaptus Therap
INDP-D101, NCT05651022: Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Recruiting
1/2
120
US
Decoy20, Tislelizumab
Indaptus Therapeutics, Inc, Translational Drug Development
Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
06/27
09/27

Download Options